Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab.
Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab.
复制标题
DOI：
10.1016/j.jiac.2021.11.018
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Tachikawa N
中科院分区：
文献类型：
--
作者：
Horiuchi H;Sasaki H;Miyazaki K;Miyata N;Yoshimura Y;Tachikawa N
据报道，淋巴瘤会恶化COVID-19的预后，部分原因是它会干扰抗体的正常产生。我们治疗了一名用利妥昔单抗治疗的套细胞淋巴瘤患者，他患上了严重的COVID-19，病毒脱落持续了78天。他在重症监护室住了28天，对任何COVID-19治疗都没有反应。尽管没有抗SARS-CoV-2-IgG，但他休息时增加的需氧量最终消退。这一病例说明，从COVID-19中康复可以在没有抗体产生的情况下发生，即使是无法产生抗体的患者也可以从严重的COVID-19中康复。它还表明，如果可以克服急性肺损伤，在利妥昔单抗治疗期间发生严重COVID-19的淋巴瘤患者可以从长期病毒脱落状态中恢复。
Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
12.8
作者：
Cattaneo C;Cancelli V;Imberti L;Dobbs K;Sottini A;Pagani C;Belotti A;Re A;Anastasia A;Quaresima V;Tucci A;Chiorini JA;Su HC;Cohen JI;Burbelo PD;Rossi G;Notarangelo LD
通讯作者：
Notarangelo LD
影响因子：
4.7
作者：
Kos, Igor;Balensiefer, Benedikt;Kaddu-Mulindwa, Dominic
通讯作者：
Kaddu-Mulindwa, Dominic
影响因子：
6.5
作者：
Marasco V;Carniti C;Guidetti A;Farina L;Magni M;Miceli R;Calabretta L;Verderio P;Ljevar S;Serpenti F;Morelli D;Apolone G;Ippolito G;Agrati C;Corradini P
通讯作者：
Corradini P
影响因子：
11.8
作者：
Schwarzkopf S;Krawczyk A;Knop D;Klump H;Heinold A;Heinemann FM;Thümmler L;Temme C;Breyer M;Witzke O;Dittmer U;Lenz V;Horn PA;Lindemann M
通讯作者：
Lindemann M